Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial.
Roy M FleischmannDaniel F AlvarezAmy E BockCarol CronenbergerIvana VranicWuyan ZhangRieke AltenPublished in: Arthritis research & therapy (2021)
ClinicalTrials.gov , NCT02480153. First posted on June 24, 2015; EU Clinical Trials Register; EudraCT number: 2014-000352-29. Start date, October 27, 2014.
Keyphrases
- clinical trial
- double blind
- rheumatoid arthritis
- placebo controlled
- juvenile idiopathic arthritis
- hidradenitis suppurativa
- phase ii
- ulcerative colitis
- phase iii
- electronic health record
- study protocol
- open label
- disease activity
- medical education
- randomized controlled trial
- systemic lupus erythematosus
- stem cells
- data analysis
- deep learning